Cardioscore
The polygenic DNA test to identify Coronary Artery Disease (CAD) risk
- CardioScore identifies patients who have the same risk of developing CAD as carriers of familial hypercholesterolemia even in the absence of elevated risk from traditional factors like elevated LDL cholesterol levels.
- CardioScore analyses an individual’s unique genetic data at 1.9 million common genetic variants. Although each variant has a small effect on CAD risk, combined they provide a powerful way of prediting CAD risk.
- CardioScore’s polygenic risk score has higher predictive power than traditional risk factors and is independent of family history.
- CardioScore’s polygenic risk score provides actionable information. Patients with high polygenic risk scores can reduce their absolute risk of CAD by almost 50% by modifying their lifestyle, bringing them in line with the average risk across the population.
- CardioScore can be used to identify patients who will have a greater benefit from statin use. Patients with high polygenic risk scores that use statins can achieve a 44% reduction in CAD risk compared to 24% risk reduction in those without a high polygenic score
Predictive power of traditional risk factors and Polygenic score in 434,837 UK Biobank participants
Adapted from Inouye et al.“Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention”,Journal of the American College of Cardiology, 2018
Cumulative absolute risk of developing Coronary Artery Disease (CAD) in UK Biobank population stratified by different percentiles of the Polygenic Risk Score (PRS)
Prevalence gradient for Coronary Artery Disease (CAD) across the distribution of the Polygenic Risk Score in UK Biobank population. Each point represents a different percentile of the PRS distribution
Latest news from Cardioscore
At the “ESC 2019 together with World Congress of Cardiology”, held in Paris in the first week of September, Allelica presented the newly developed software to compute Polygenic Risk Score (PRS) for coronary artery diseases. The clinical value of integrating PRS in traditional risk models was also discussed.
Come to meet us in Houston, Texas, at the annual conference of the American Society of Human Genetics, the largest and most exciting human genetic conference in the world. See you at booth #200 from the 15th to the 19th of October. The meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics.
© 2019 Allelica